Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial
Authors' conclusion
5HT1B receptors have a glucoregulatory role in humans, probably acting on insulin secretion, insulin sensitivity and glucose effectiveness.
Study context
- Population
- Overweight adults, otherwise healthycross-over
- Participants
- 10 adults
- Comparison
- Sumatriptan vs placebo
Methodological detailscross-over, double-blinded, placebo-controlled, two-visit random-order, 60-min IV glucose tolerance test followed by 120-min hyperinsulinaemic euglycaemic clamp
- Cross-over
- Double-blinded
- Placebo-controlled
- Two-visit random-order
- 60-min IV glucose tolerance test followed by 120-min hyperinsulinaemic euglycaemic clamp
Primary result
As reported in the abstract
Glucose excursion during IV glucose tolerance test (iAUC0-60 min)
P = 0.047
Further findings
Circulating insulin (iAUC0-10 min) · reduced with sumatriptan
P = 0.005
Insulin sensitivity (M/I-value) · reduced with sumatriptan
P = 0.010
Glucose effectiveness (SG) · reduced with sumatriptan
P = 0.027
Original publication
Sumatriptan, a serotonin 5HT 1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial. Diabetes Obes Metab. Published 13 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →